The pharmaceutical landscape is entering a pivotal era of transformation. With the Inflation Reduction Act’s Maximum Fair Price (MFP) provisions coming into force, the HRSA 340B pilot redefining compliance benchmarks, and broader political and economic forces influencing pharma today, manufacturers must stay informed to prepare for revenue management impacts.
Join our panel of industry experts as they unpack the evolving policy landscape, executive actions, and market dynamics that are redefining pharma revenue management and compliance. This session will equip you with the insights and foresight needed to stay ahead of change.
We’ll discuss:
Gain clarity on where U.S. pharma policy is headed—and what steps your organization can take now to strengthen compliance, manage risk, and protect revenue integrity.
